TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
TLSI Stock Chart & Stats
$4.24
-$0.05(-0.97%)
At close: 4:00 PM EST
$4.24
-$0.05(-0.97%)
Day’s Range― - ―
52-Week Range$3.42 - $7.95
Previous CloseN/A
Volume4.84K
Average Volume (3M)227.57K
Market Cap
$259.94M
Enterprise Value$174.74M
Total Cash (Recent Filing)$20.44M
Total Debt (Recent Filing)$34.44M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 14, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding61,306,440
10 Day Avg. Volume200,051
30 Day Avg. Volume227,568
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)-7.81
Price to Sales (P/S)5.86
P/FCF Ratio-13.97
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit4.58
Enterprise Value/Ebitda-6.24
Forecast
1Y Price Target
$9.20Price Target Upside116.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$59.96M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence For Delivery PlatformPeer-reviewed research showed that delivering nelitolimod with the pressure-enabled drug delivery platform achieved greater drug distribution in and around tumors, reduced immune-suppressive cells and increased tumor-killing immune cells, supporting potential partnerships for targeted intratumoral therapies.
Expansion Into New Clinical IndicationsClinical results and key opinion leader discussions highlight TriNav's potential in uterine fibroid and multinodular goiter treatments, while a pilot trial for genicular artery embolization supports expansion into additional therapeutic indications.
Product Portfolio ExpansionLaunch of TriNav FLX and the planned TriNav Advance broaden the product lineup by improving navigation and compatibility with standard microcatheters, which could expand the addressable market and drive procedure-related sales.
Bears Say
Commercial Execution And Market UptakeInvestments in commercial infrastructure are raising cash burn as new sales hires ramp to productivity, and early market reception to recent product launches has been modest, creating uneven revenue growth.
Profitability And Cash ResilienceReported adjusted losses exceeded expectations and the company did not provide explicit profitability guidance, while ongoing cash consumption raises concerns about near-term financial resilience.
Share Dilution RiskRecent equity financing and outstanding convertible securities have increased the share count and could dilute existing shareholders, prompting analysts to lower price targets and adjust financial models.
TriSalus Life Sciences News
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.42 and its highest was $7.95 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $259.94M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is May 14, 2026 which is in 40 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Mar 05, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.068.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.16.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 61,306,440 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -6.394%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.20 (116.98% Upside)
$9.20 (116.98% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 68.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.00%
12-Months-Change
Fundamentals
Return on Equity
137.18%
Trailing 12-Months
Asset Growth
47.39%
Trailing 12-Months
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
TLSI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum and sizable top-line growth (Q4 revenue +60% YoY; FY revenue +53%), improved quarterly profitability metrics (higher gross margin and much smaller adjusted EBITDA loss), successful product launches and an oversubscribed $46M financing to fund an aggressive commercial and clinical expansion. Notable negatives include a delayed nelitolimod data release (rescheduled to H2 2026), earlier-year manufacturing inefficiencies that modestly pressured full-year gross margin, higher one-time G&A charges, a worse GAAP loss per share due to capital structure changes, and near-term execution/timing risk as the company ramps its enlarged sales organization. Overall, the positive commercial and financing developments and improving operating performance outweigh the timing and one-time challenges, supporting a favorable outlook while acknowledging execution risk tied to the expansion and product clearance timing.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$9.20
▲(116.98% Upside)
Technical Analysis
Ownership Overview
11.67% Insiders
3.20% Mutual Funds
9.59% Other Institutional Investors
71.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---